UK markets closed
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • FTSE 250

    22,522.18
    +50.14 (+0.22%)
     
  • AIM

    1,254.25
    +6.12 (+0.49%)
     
  • GBP/EUR

    1.1538
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.3842
    +0.0058 (+0.42%)
     
  • BTC-GBP

    44,949.18
    +236.47 (+0.53%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • DOW

    34,200.67
    +164.68 (+0.48%)
     
  • CRUDE OIL

    63.07
    -0.39 (-0.61%)
     
  • GOLD FUTURES

    1,777.30
    +10.50 (+0.59%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • HANG SENG

    28,969.71
    +176.57 (+0.61%)
     
  • DAX

    15,459.75
    +204.42 (+1.34%)
     
  • CAC 40

    6,287.07
    +52.93 (+0.85%)
     

Global Xerostomia (Dry Mouth) Therapeutics Market to Reach $826.3 Million by 2027

ReportLinker
·25-min read

Abstract: - Global Xerostomia (Dry Mouth) Therapeutics Market to Reach $826. 3 Million by 2027. - Amid the COVID-19 crisis, the global market for Xerostomia (Dry Mouth) Therapeutics estimated at US$659.

New York, April 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Xerostomia (Dry Mouth) Therapeutics Industry" - https://www.reportlinker.com/p06033322/?utm_source=GNW
7 Million in the year 2020, is projected to reach a revised size of US$826.3 Million by 2027, growing at aCAGR of 3.3% over the period 2020-2027. Over-the-Counter, one of the segments analyzed in the report, is projected to record 3.4% CAGR and reach US$494 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Prescription segment is readjusted to a revised 3.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $178.5 Million, While China is Forecast to Grow at 5.2% CAGR
- The Xerostomia (Dry Mouth) Therapeutics market in the U.S. is estimated at US$178.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.3 Million by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

- Select Competitors (Total 36 Featured) -

  • 3M company

  • Advanz Pharma Corp. Limited

  • Bausch Health Companies Inc.

  • Fresenius SE & Co. KGaA

  • GlaxoSmithKline PLC

  • Hikma Pharmaceuticals PLC

  • Lupin Limited

  • Parnell Pharmaceuticals Inc.

  • Pharmascience Inc (Pendopharm)

  • Quest Products Inc.




Read the full report: https://www.reportlinker.com/p06033322/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Over-the-Counter
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Over-the-Counter by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Over-the-Counter by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Prescription by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Prescription by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Prescription by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Dentifrices by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Dentifrices by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Dentifrices by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Salivary
Stimulants by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Salivary Stimulants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Salivary Stimulants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Salivary
Substitutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Salivary Substitutes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Salivary Substitutes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 19: USA Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 20: USA Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 21: USA 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 22: USA Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 23: USA Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 24: USA 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

CANADA
Table 25: Canada Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 26: Canada Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 27: Canada 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 28: Canada Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 29: Canada Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 30: Canada 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

JAPAN
Table 31: Japan Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 32: Japan Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 33: Japan 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 34: Japan Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 35: Japan Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 36: Japan 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

CHINA
Table 37: China Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 38: China Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 39: China 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 40: China Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 41: China Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 42: China 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

EUROPE
Table 43: Europe Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 44: Europe Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 45: Europe 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 46: Europe Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: Europe Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 48: Europe 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 49: Europe Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Europe Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 51: Europe 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

FRANCE
Table 52: France Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 53: France Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 54: France 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 55: France Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 56: France Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 57: France 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

GERMANY
Table 58: Germany Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 59: Germany Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 60: Germany 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Type - Percentage Breakdown of Value
Sales for Over-the-Counter and Prescription for the Years 2012,
2020 & 2027

Table 61: Germany Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 62: Germany Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 63: Germany 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Percentage Breakdown
of Value Sales for Dentifrices, Salivary Stimulants and
Salivary Substitutes for the Years 2012, 2020 & 2027

ITALY
Table 64: Italy Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: Italy Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 66: Italy 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 67: Italy Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: Italy Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 69: Italy 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 70: UK Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 71: UK Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 72: UK 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 73: UK Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 74: UK Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 75: UK 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

SPAIN
Table 76: Spain Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 77: Spain Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 78: Spain 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 79: Spain Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: Spain Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 81: Spain 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

RUSSIA
Table 82: Russia Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 83: Russia Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 84: Russia 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 85: Russia Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 86: Russia Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 87: Russia 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 88: Rest of Europe Current & Future Analysis for
Xerostomia (Dry Mouth) Therapeutics by Type - Over-the-Counter
and Prescription - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 89: Rest of Europe Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 90: Rest of Europe 15-Year Perspective for Xerostomia
(Dry Mouth) Therapeutics by Type - Percentage Breakdown of
Value Sales for Over-the-Counter and Prescription for the Years
2012, 2020 & 2027

Table 91: Rest of Europe Current & Future Analysis for
Xerostomia (Dry Mouth) Therapeutics by Product Segment -
Dentifrices, Salivary Stimulants and Salivary Substitutes -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 92: Rest of Europe Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 93: Rest of Europe 15-Year Perspective for Xerostomia
(Dry Mouth) Therapeutics by Product Segment - Percentage
Breakdown of Value Sales for Dentifrices, Salivary Stimulants
and Salivary Substitutes for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 94: Asia-Pacific Current & Future Analysis for Xerostomia
(Dry Mouth) Therapeutics by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 95: Asia-Pacific Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 96: Asia-Pacific 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Geographic Region - Percentage Breakdown
of Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 97: Asia-Pacific Current & Future Analysis for Xerostomia
(Dry Mouth) Therapeutics by Type - Over-the-Counter and
Prescription - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 98: Asia-Pacific Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 99: Asia-Pacific 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Type - Percentage Breakdown of Value
Sales for Over-the-Counter and Prescription for the Years 2012,
2020 & 2027

Table 100: Asia-Pacific Current & Future Analysis for
Xerostomia (Dry Mouth) Therapeutics by Product Segment -
Dentifrices, Salivary Stimulants and Salivary Substitutes -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 101: Asia-Pacific Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Percentage Breakdown
of Value Sales for Dentifrices, Salivary Stimulants and
Salivary Substitutes for the Years 2012, 2020 & 2027

AUSTRALIA
Table 103: Australia Current & Future Analysis for Xerostomia
(Dry Mouth) Therapeutics by Type - Over-the-Counter and
Prescription - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 104: Australia Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 105: Australia 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Type - Percentage Breakdown of Value
Sales for Over-the-Counter and Prescription for the Years 2012,
2020 & 2027

Table 106: Australia Current & Future Analysis for Xerostomia
(Dry Mouth) Therapeutics by Product Segment - Dentifrices,
Salivary Stimulants and Salivary Substitutes - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 107: Australia Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 108: Australia 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Percentage Breakdown
of Value Sales for Dentifrices, Salivary Stimulants and
Salivary Substitutes for the Years 2012, 2020 & 2027

INDIA
Table 109: India Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 110: India Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 111: India 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Type - Percentage Breakdown of Value Sales for
Over-the-Counter and Prescription for the Years 2012, 2020 &
2027

Table 112: India Current & Future Analysis for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 113: India Historic Review for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 114: India 15-Year Perspective for Xerostomia (Dry Mouth)
Therapeutics by Product Segment - Percentage Breakdown of Value
Sales for Dentifrices, Salivary Stimulants and Salivary
Substitutes for the Years 2012, 2020 & 2027

SOUTH KOREA
Table 115: South Korea Current & Future Analysis for Xerostomia
(Dry Mouth) Therapeutics by Type - Over-the-Counter and
Prescription - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 116: South Korea Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 117: South Korea 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Type - Percentage Breakdown of Value
Sales for Over-the-Counter and Prescription for the Years 2012,
2020 & 2027

Table 118: South Korea Current & Future Analysis for Xerostomia
(Dry Mouth) Therapeutics by Product Segment - Dentifrices,
Salivary Stimulants and Salivary Substitutes - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 119: South Korea Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Dentifrices, Salivary
Stimulants and Salivary Substitutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 120: South Korea 15-Year Perspective for Xerostomia (Dry
Mouth) Therapeutics by Product Segment - Percentage Breakdown
of Value Sales for Dentifrices, Salivary Stimulants and
Salivary Substitutes for the Years 2012, 2020 & 2027

REST OF ASIA-PACIFIC
Table 121: Rest of Asia-Pacific Current & Future Analysis for
Xerostomia (Dry Mouth) Therapeutics by Type - Over-the-Counter
and Prescription - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 122: Rest of Asia-Pacific Historic Review for Xerostomia
(Dry Mouth) Therapeutics by Type - Over-the-Counter and
Prescription Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 123: Rest of Asia-Pacific 15-Year Perspective for
Xerostomia (Dry Mouth) Therapeutics by Type - Percentage
Breakdown of Value Sales for Over-the-Counter and Prescription
for the Years 2012, 2020 & 2027

Table 124: Rest of Asia-Pacific Current & Future Analysis for
Xerostomia (Dry Mouth) Therapeutics by Product Segment -
Dentifrices, Salivary Stimulants and Salivary Substitutes -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 125: Rest of Asia-Pacific Historic Review for Xerostomia
(Dry Mouth) Therapeutics by Product Segment - Dentifrices,
Salivary Stimulants and Salivary Substitutes Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 126: Rest of Asia-Pacific 15-Year Perspective for
Xerostomia (Dry Mouth) Therapeutics by Product Segment -
Percentage Breakdown of Value Sales for Dentifrices, Salivary
Stimulants and Salivary Substitutes for the Years 2012, 2020 &
2027

LATIN AMERICA
Table 127: Latin America Current & Future Analysis for
Xerostomia (Dry Mouth) Therapeutics by Geographic Region -
Argentina, Brazil, Mexico and Rest of Latin America Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 128: Latin America Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Geographic Region - Argentina, Brazil,
Mexico and Rest of Latin America Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 129: Latin America 15-Year Perspective for Xerostomia
(Dry Mouth) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest
of Latin America Markets for Years 2012, 2020 & 2027

Table 130: Latin America Current & Future Analysis for
Xerostomia (Dry Mouth) Therapeutics by Type - Over-the-Counter
and Prescription - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 131: Latin America Historic Review for Xerostomia (Dry
Mouth) Therapeutics by Type - Over-the-Counter and Prescription

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033322/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001